Search Within

Jedd D Wolchok

  1. "Advanced Practice Providers"
Formats
  1. Meeting Abstract (14)
  2. Journal Article (12)
  3. Research Letter (1)
Groups
  1. Advanced Practice Providers (27)
  2. Department of Medicine (27)
  3. GSK Faculty (27)
  4. Melanoma and Immunotherapeutics Service (27)
  5. Solid Tumor Oncology Division (27)
  6. Nursing (26)

More Groups

People
  1. Ruthann Gordon (20)
  2. Margaret Callahan (13)
  3. Michael Postow (11)
  4. Jianda Yuan (10)
  5. Paul Chapman (9)
  6. Alexander Lesokhin (8)

More People

Years
  1. 2020 (1)
  2. 2017 (2)
  3. 2016 (3)
  4. 2015 (1)
  5. 2014 (4)
  6. 2013 (2)

More Years

Publications
  1. Journal of Clinical Oncology (12)
  2. Annals of Oncology (2)
  3. Cancer Immunology Research (2)
  4. New England Journal of Medicine (2)
  5. Asia-Pacific Journal of Clinical Oncology (1)
  6. Cancer Immunity (1)

More Publications

Publishers
  1. American Society of Clinical Oncology (12)
  2. American Association for Cancer Research (3)
  3. Massachusetts Medical Society (2)
  4. Oxford University Press (2)
  5. Academy of Cancer Immunology (1)
  6. American Medical Association (1)

More Publishers

Results (27)

Export to EndNote / Excel | PubMed

Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Determinants of COVID-19 disease severity in patients with cancer
    Research Letter

    Robilotti, E. V.; Babady, N. E.; Mead, P. A.; Rolling, T.; Perez-Johnston, R.; Bernardes, M.; Bogler, Y.; Caldararo, M.; Figueroa, C. J.; Glickman, M. S.; more...
    Nature Medicine (2020)

    Fulltext@MSK | Save
  • Antibody-mediated thyroid dysfunction during T-cell checkpoint blockade in patients with non-small-cell lung cancer
    Journal Article

    Osorio, J. C.; Ni, A.; Chaft, J. E.; Pollina, R.; Kasler, M. K.; Stephens, D.; Rodriguez, C.; Cambridge, L.; Rizvi, H.; Wolchok, J. D.; more...
    Annals of Oncology (2017)

    Fulltext@MSK | Save
  • Pneumonitis in patients treated with anti-programmed death-1/programmed death ligand 1 therapy
    Journal Article

    Naidoo, J.; Wang, X.; Woo, K. M.; Iyriboz, T.; Halpenny, D.; Cunningham, J.; Chaft, J. E.; Segal, N. H.; Callahan, M. K.; Lesokhin, A. M.; more...
    Journal of Clinical Oncology (2017)

    Fulltext@MSK | Save
  • Efficacy of nivolumab and ipilimumab (Nivo + Ipi) combination in melanoma patients (pts) treated at a single institution on an expanded-access program (EAP)
    Meeting Abstract

    Shoushtari, A. N.; Navid-Azarbaijani, P.; Friedman, C. F.; Panageas, K.; Postow, M. A.; Callahan, M. K.; Momtaz, P.; Campbell, S. C.; Shames, Y.; Prempeh-Keteku, N. A.; more...
    Journal of Clinical Oncology (2016)

    Fulltext@MSK | Save
  • Toxicity associated with ipilimumab and nivolumab (Ipi plus Nivo) combination therapy in melanoma patients (pts) treated at a single-institution under an expanded-access program (EAP)
    Meeting Abstract

    Friedman, C. F.; Navid-Azarbaijani, P.; Shoushtari, A. N.; Campbell, S. C.; Callahan, M. K.; Momtaz, P.; Prempeh-Keteku, N. A.; Postow, M. A.; Shames, Y.; Wolchok, J. D.; more...
    Journal of Clinical Oncology (2016)

    Fulltext@MSK | Save
  • Autoimmune bullous skin disorders with immune checkpoint inhibitors targeting PD-1 and PD-L1
    Journal Article

    Naidoo, J.; Schindler, K.; Querfeld, C.; Busam, K.; Cunningham, J.; Page, D. B.; Postow, M. A.; Weinstein, A.; Lucas, A. S.; Ciccolini, K. T.; more...
    Cancer Immunology Research (2016)

    Fulltext@MSK | Save
  • Incidence and management of interstitial lung disease in patients with advanced cancer treated with anti-programmed death receptor 1 ligand pembrolizumab
    Meeting Abstract

    Albano, M.; Gordon, R. A.; Rizvi, N. A.; Wolchok, J. D.
    Oncology Nursing Forum (2015)

    Fulltext@MSK | Save
  • Survival, response duration, and activity by BRAF mutation (MT) status of nivolumab (NIVO, anti-PD-1, BMS-936558, ONO-4538) and ipilimumab (IPI) concurrent therapy in advanced melanoma (MEL)
    Meeting Abstract

    Sznol, M.; Kluger, H. M.; Callahan, M. K.; Postow, M. A.; Gordon, R. A.; Segal, N. H.; Rizvi, N. A.; Lesokhin, A. M.; Atkins, M. B.; Kirkwood, J. M.; more...
    Journal of Clinical Oncology (2014)

    Fulltext@MSK | Save
  • Survival, response duration, and activity by BRAF mutation (MT) status in a phase 1 trial of nivolumab (anti-PD-1, BMS-936558, ONO-4538) and ipilimumab (IPI) concurrent therapy in advanced melanoma (MEL)
    Meeting Abstract

    Kluger, H.; Sznol, M.; Callahan, M.; Postow, M.; Gordon, R.; Segal, N. H.; Rizvi, N.; Lesokhin, A.; Atkins, M. B.; Kirkwood, J.; more...
    Annals of Oncology (2014)

    Fulltext@MSK | Save
  • Survival, response duration, and activity by BRAF mutation (MT) status of nivolumab (NIVO, anti-programmed death-1) and ipilimumab (IPI) concurrent therapy in advanced melanoma (MEL)
    Meeting Abstract

    Sznol, M.; Kluger, H.; Callahan, M. K.; Postow, M. A.; Gordon, R.; Seal, N. H.; Rizvi, N. A.; Lesokhin, A. M.; Atkins, M. B.; Kirkwood, J. M.; more...
    Asia-Pacific Journal of Clinical Oncology (2014)

    Fulltext@MSK | Save